Switch theme
Sign up to access all valuation multiples
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
1970
3.9K+
LTM Revenue $1.3B
LTM EBITDA $270M
$2.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Conmed has a last 12-month revenue (LTM) of $1.3B and a last 12-month EBITDA of $270M.
In the most recent fiscal year, Conmed achieved revenue of $1.3B and an EBITDA of $272M.
Conmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Conmed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Profit | $750M | XXX | $733M | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $270M | XXX | $272M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $205M | XXX | $200M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $133M | XXX | $132M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $881M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Conmed's stock price is $57.
Conmed has current market cap of $1.8B, and EV of $2.6B.
See Conmed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.6B | $1.8B | XXX | XXX | XXX | XXX | $4.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Conmed has market cap of $1.8B and EV of $2.6B.
Conmed's trades at 2.0x EV/Revenue multiple, and 9.6x EV/EBITDA.
Equity research analysts estimate Conmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Conmed has a P/E ratio of 13.2x.
See valuation multiples for Conmed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 12.7x | XXX | 13.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.2x | XXX | 13.3x | XXX | XXX | XXX |
| EV/FCF | 17.5x | XXX | 17.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialConmed's last 12 month revenue growth is 5%
Conmed's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Conmed's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Conmed's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Conmed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Conmed acquired XXX companies to date.
Last acquisition by Conmed was XXXXXXXX, XXXXX XXXXX XXXXXX . Conmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Conmed founded? | Conmed was founded in 1970. |
| Where is Conmed headquartered? | Conmed is headquartered in United States of America. |
| How many employees does Conmed have? | As of today, Conmed has 3.9K+ employees. |
| Who is the CEO of Conmed? | Conmed's CEO is Mr. Patrick J. Beyer. |
| Is Conmed publicy listed? | Yes, Conmed is a public company listed on NYS. |
| What is the stock symbol of Conmed? | Conmed trades under CNMD ticker. |
| When did Conmed go public? | Conmed went public in 1987. |
| Who are competitors of Conmed? | Similar companies to Conmed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Conmed? | Conmed's current market cap is $1.8B |
| What is the current revenue of Conmed? | Conmed's last 12 months revenue is $1.3B. |
| What is the current revenue growth of Conmed? | Conmed revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Conmed? | Current revenue multiple of Conmed is 2.0x. |
| Is Conmed profitable? | Yes, Conmed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Conmed? | Conmed's last 12 months EBITDA is $270M. |
| What is Conmed's EBITDA margin? | Conmed's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Conmed? | Current EBITDA multiple of Conmed is 9.7x. |
| What is the current FCF of Conmed? | Conmed's last 12 months FCF is $149M. |
| What is Conmed's FCF margin? | Conmed's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Conmed? | Current FCF multiple of Conmed is 17.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
